Share Price and Basic Stock Data
Last Updated: October 22, 2025, 5:28 am
| PEG Ratio | 3.49 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Abbott India Ltd operates in the pharmaceuticals sector, delivering a robust performance with sales reported at ₹5,349 Cr for FY 2023, an increase from ₹4,913 Cr in FY 2022. The company’s quarterly sales have shown a consistent upward trajectory, reaching ₹1,494 Cr in Sep 2023, up from ₹1,343 Cr in Mar 2023. Notably, the operating profit margin (OPM) stood at 23% for Mar 2024, reflecting operational efficiency. The growth in sales is complemented by a comprehensive product portfolio and strong brand equity, which have contributed to the company’s market capitalization of ₹64,026 Cr. Furthermore, the sales forecast indicates a continued upward trend, with quarterly sales expected to rise to ₹1,738 Cr by Jun 2025. This growth trajectory positions Abbott India as a competitive player within the pharmaceutical industry, which is crucial for sustaining its market share against other industry leaders.
Profitability and Efficiency Metrics
Abbott India Ltd has demonstrated impressive profitability metrics, with a net profit of ₹1,414 Cr for FY 2025, an increase from ₹1,201 Cr in FY 2024. The return on equity (ROE) is reported at 35.7%, showcasing the company’s ability to generate substantial returns for shareholders. The interest coverage ratio (ICR) is remarkably high at 172.37x, indicating strong financial health and minimal risk concerning debt obligations. The cash conversion cycle (CCC) is efficiently managed at just 3 days, which is significantly lower than the industry average, suggesting effective management of inventory and receivables. However, the operating profit margin (OPM) has varied over the quarters, with a high of 27% in Dec 2023. This variability may indicate sensitivity to operational costs, yet overall, the profitability metrics reinforce Abbott India’s solid standing in the pharmaceutical sector.
Balance Sheet Strength and Financial Ratios
Abbott India Ltd’s balance sheet reflects a strong financial position, with total reserves rising to ₹4,212 Cr by Mar 2025, compared to ₹3,678 Cr in Mar 2024. The company’s borrowings stood at ₹197 Cr, indicating prudent leverage given the substantial cash reserves. The debt-to-equity ratio remains conservative, supporting a stable financial structure. Furthermore, the company reported a current ratio of 3.39, well above the industry benchmark of 2, highlighting robust liquidity to meet short-term obligations. The price-to-book value (P/BV) ratio is reported at 15.43x, which appears elevated compared to the typical sector ranges, suggesting a premium valuation that may be justified by the company’s growth prospects. Overall, Abbott India demonstrates a sound balance sheet, ensuring financial resilience amid market fluctuations.
Shareholding Pattern and Investor Confidence
The shareholding structure of Abbott India Ltd indicates strong promoter confidence, with promoters holding 74.99% of the equity. This significant stake reflects a commitment to long-term growth and stability. Foreign institutional investors (FIIs) constitute a minimal 0.16% of the shareholding, while domestic institutional investors (DIIs) hold 9.18%. The public shareholding stands at 15.67%, with a total of 67,584 shareholders. The relatively low FII participation may suggest a cautious stance among foreign investors, potentially due to global market uncertainties. However, the consistent promoter stake signals a positive outlook for existing and potential investors. The dividends paid out have also shown an upward trend, with ₹475 per share declared for Mar 2025, reflecting the company’s commitment to returning value to shareholders.
Outlook, Risks, and Final Insight
If margins sustain at current levels, Abbott India could see continued revenue growth, bolstered by its strong market position and product innovation. However, risks such as rising operational costs and regulatory challenges in the pharmaceutical sector could impact profitability. Additionally, the relatively low foreign institutional investment might pose a risk to liquidity and market sentiment. Nonetheless, the company’s robust financial metrics, including a high ROE and strong interest coverage, provide a cushion against potential downturns. If the company successfully navigates these challenges while maintaining operational efficiency, it is likely to enhance shareholder value and sustain its competitive edge in the pharmaceuticals industry. Overall, Abbott India Ltd presents a compelling case for investors seeking stability and growth in the healthcare sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Abbott India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,993 Cr. | 458 | 465/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 38.1 Cr. | 51.3 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.9 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,038.24 Cr | 1,197.65 | 50.64 | 194.07 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,304 | 1,379 | 1,322 | 1,343 | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 |
| Expenses | 1,034 | 1,036 | 1,010 | 1,063 | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 |
| Operating Profit | 270 | 343 | 312 | 280 | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 |
| OPM % | 21% | 25% | 24% | 21% | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% |
| Other Income | 27 | 34 | 44 | 50 | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 |
| Interest | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 |
| Depreciation | 17 | 17 | 18 | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 |
| Profit before tax | 275 | 355 | 335 | 308 | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 |
| Tax % | 25% | 25% | 26% | 25% | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% |
| Net Profit | 206 | 266 | 247 | 231 | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 |
| EPS in Rs | 96.77 | 124.95 | 116.16 | 108.91 | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 |
Last Updated: August 20, 2025, 12:45 am
Below is a detailed analysis of the quarterly data for Abbott India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,738.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,605.00 Cr. (Mar 2025) to 1,738.00 Cr., marking an increase of 133.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,293.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,176.00 Cr. (Mar 2025) to 1,293.00 Cr., marking an increase of 117.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 446.00 Cr.. The value appears strong and on an upward trend. It has increased from 429.00 Cr. (Mar 2025) to 446.00 Cr., marking an increase of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2025) to 73.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 493.00 Cr.. The value appears strong and on an upward trend. It has increased from 483.00 Cr. (Mar 2025) to 493.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 26.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 366.00 Cr.. The value appears to be declining and may need further review. It has decreased from 367.00 Cr. (Mar 2025) to 366.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 172.18. The value appears to be declining and may need further review. It has decreased from 172.73 (Mar 2025) to 172.18, marking a decrease of 0.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,849 | 6,409 | 6,590 |
| Expenses | 2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 4,841 |
| Operating Profit | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,082 | 1,206 | 1,453 | 1,695 | 1,749 |
| OPM % | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income | 49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 83 | 154 | 248 | 275 | 281 |
| Interest | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 14 |
| Depreciation | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 73 |
| Profit before tax | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 1,943 |
| Tax % | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | |
| Net Profit | 198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,452 |
| EPS in Rs | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 683.45 |
| Dividend Payout % | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.35% | 8.63% | 44.77% | 12.22% | 31.78% | 16.53% | 15.63% | 18.77% | 26.55% | 17.74% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.73% | 36.14% | -32.55% | 19.56% | -15.25% | -0.90% | 3.14% | 7.78% | -8.82% |
Abbott India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 32% |
| 3 Years: | 34% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: July 25, 2025, 2:01 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 |
| Other Liabilities | 351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 |
| Total Liabilities | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 |
| Fixed Assets | 98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 |
| CWIP | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 |
| Total Assets | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 |
Below is a detailed analysis of the balance sheet data for Abbott India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 21.00 Cr..
- For Reserves, as of Mar 2025, the value is 4,212.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,678.00 Cr. (Mar 2024) to 4,212.00 Cr., marking an increase of 534.00 Cr..
- For Borrowings, as of Mar 2025, the value is 197.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 83.00 Cr. (Mar 2024) to 197.00 Cr., marking an increase of 114.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1,487.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,411.00 Cr. (Mar 2024) to 1,487.00 Cr., marking an increase of 76.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 5,917.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,193.00 Cr. (Mar 2024) to 5,917.00 Cr., marking an increase of 724.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 336.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2024) to 336.00 Cr., marking an increase of 111.00 Cr..
- For CWIP, as of Mar 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 18.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 5,563.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,958.00 Cr. (Mar 2024) to 5,563.00 Cr., marking an increase of 605.00 Cr..
- For Total Assets, as of Mar 2025, the value is 5,917.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,193.00 Cr. (Mar 2024) to 5,917.00 Cr., marking an increase of 724.00 Cr..
Notably, the Reserves (4,212.00 Cr.) exceed the Borrowings (197.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 267.00 | 312.00 | 365.00 | 398.00 | 525.00 | 605.00 | 582.00 | 769.00 | -151.00 | -112.00 | -82.00 | -196.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 |
| Inventory Days | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 |
| Days Payable | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 |
| Cash Conversion Cycle | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 |
| Working Capital Days | 36 | 30 | 32 | 21 | 63 | 22 | 10 | 7 | -7 | -8 | -14 | 97 |
| ROCE % | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis Midcap Fund | 164,230 | 1.73 | 425.47 | 164,230 | 2025-04-22 17:25:15 | 0% |
| SBI Large & Midcap Fund | 155,000 | 2.01 | 401.56 | 155,000 | 2025-04-22 17:25:15 | 0% |
| SBI Magnum Global Fund | 133,000 | 5.29 | 344.56 | 133,000 | 2025-04-22 17:25:15 | 0% |
| Canara Robeco Emerging Equities | 112,506 | 1.46 | 291.47 | 112,506 | 2025-04-22 17:25:15 | 0% |
| HSBC Midcap Fund | 77,272 | 2.11 | 200.19 | 77,272 | 2025-04-22 17:25:15 | 0% |
| Nippon India Pharma Fund | 76,390 | 2.87 | 197.9 | 76,390 | 2025-04-22 17:25:15 | 0% |
| PGIM India Midcap Opportunities Fund | 66,361 | 1.73 | 171.92 | 66,361 | 2025-04-22 17:25:15 | 0% |
| Franklin India Prima Fund | 52,304 | 1.34 | 135.5 | 52,304 | 2025-04-22 17:25:15 | 0% |
| Nippon India Multi Cap Fund | 44,742 | 0.45 | 115.91 | 44,742 | 2025-04-22 17:25:15 | 0% |
| Canara Robeco Flexi Cap Fund | 42,310 | 0.94 | 109.61 | 42,310 | 2025-04-22 17:25:15 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Diluted EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Cash EPS (Rs.) | 699.41 | 598.77 | 479.71 | 406.96 | 352.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Dividend / Share (Rs.) | 475.00 | 410.00 | 325.00 | 275.00 | 275.00 |
| Revenue From Operations / Share (Rs.) | 3016.07 | 2752.43 | 2517.05 | 2314.95 | 2028.24 |
| PBDIT / Share (Rs.) | 927.14 | 800.64 | 639.90 | 548.20 | 471.70 |
| PBIT / Share (Rs.) | 893.36 | 767.15 | 606.97 | 517.10 | 444.34 |
| PBT / Share (Rs.) | 887.98 | 761.29 | 599.44 | 508.11 | 435.74 |
| Net Profit / Share (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 |
| PBDIT Margin (%) | 30.74 | 29.08 | 25.42 | 23.68 | 23.25 |
| PBIT Margin (%) | 29.61 | 27.87 | 24.11 | 22.33 | 21.90 |
| PBT Margin (%) | 29.44 | 27.65 | 23.81 | 21.94 | 21.48 |
| Net Profit Margin (%) | 22.06 | 20.53 | 17.75 | 16.23 | 16.02 |
| Return on Networth / Equity (%) | 33.41 | 32.47 | 29.77 | 28.32 | 26.54 |
| Return on Capital Employeed (%) | 42.09 | 42.33 | 38.50 | 36.37 | 33.60 |
| Return On Assets (%) | 23.90 | 23.12 | 20.84 | 18.90 | 17.98 |
| Asset Turnover Ratio (%) | 1.15 | 1.20 | 1.22 | 1.22 | 1.17 |
| Current Ratio (X) | 3.39 | 2.42 | 2.51 | 3.20 | 3.41 |
| Quick Ratio (X) | 2.76 | 1.96 | 1.97 | 2.63 | 2.72 |
| Inventory Turnover Ratio (X) | 8.54 | 9.22 | 0.83 | 0.70 | 0.72 |
| Dividend Payout Ratio (NP) (%) | 61.59 | 57.49 | 61.54 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 58.61 | 54.27 | 57.32 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 38.41 | 42.51 | 38.46 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 41.39 | 45.73 | 42.68 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 172.37 | 136.66 | 85.04 | 60.99 | 54.83 |
| Interest Coverage Ratio (Post Tax) (X) | 124.75 | 97.48 | 60.38 | 42.82 | 38.78 |
| Enterprise Value (Cr.) | 63674.71 | 55125.76 | 44996.86 | 34862.11 | 29441.84 |
| EV / Net Operating Revenue (X) | 9.93 | 9.42 | 8.41 | 7.09 | 6.83 |
| EV / EBITDA (X) | 32.32 | 32.40 | 33.09 | 29.93 | 29.37 |
| MarketCap / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| Retention Ratios (%) | 38.40 | 42.50 | 38.45 | 0.00 | 0.00 |
| Price / BV (X) | 15.43 | 15.48 | 14.72 | 13.34 | 12.24 |
| Price / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Abbott India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 699.41. This value is within the healthy range. It has increased from 598.77 (Mar 24) to 699.41, marking an increase of 100.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Dividend / Share (Rs.), as of Mar 25, the value is 475.00. This value exceeds the healthy maximum of 3. It has increased from 410.00 (Mar 24) to 475.00, marking an increase of 65.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3,016.07. It has increased from 2,752.43 (Mar 24) to 3,016.07, marking an increase of 263.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 927.14. This value is within the healthy range. It has increased from 800.64 (Mar 24) to 927.14, marking an increase of 126.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 893.36. This value is within the healthy range. It has increased from 767.15 (Mar 24) to 893.36, marking an increase of 126.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 887.98. This value is within the healthy range. It has increased from 761.29 (Mar 24) to 887.98, marking an increase of 126.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For PBDIT Margin (%), as of Mar 25, the value is 30.74. This value is within the healthy range. It has increased from 29.08 (Mar 24) to 30.74, marking an increase of 1.66.
- For PBIT Margin (%), as of Mar 25, the value is 29.61. This value exceeds the healthy maximum of 20. It has increased from 27.87 (Mar 24) to 29.61, marking an increase of 1.74.
- For PBT Margin (%), as of Mar 25, the value is 29.44. This value is within the healthy range. It has increased from 27.65 (Mar 24) to 29.44, marking an increase of 1.79.
- For Net Profit Margin (%), as of Mar 25, the value is 22.06. This value exceeds the healthy maximum of 10. It has increased from 20.53 (Mar 24) to 22.06, marking an increase of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 32.47 (Mar 24) to 33.41, marking an increase of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 42.09. This value is within the healthy range. It has decreased from 42.33 (Mar 24) to 42.09, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 23.90. This value is within the healthy range. It has increased from 23.12 (Mar 24) to 23.90, marking an increase of 0.78.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.15. It has decreased from 1.20 (Mar 24) to 1.15, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 2.76. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 24) to 2.76, marking an increase of 0.80.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.54. This value exceeds the healthy maximum of 8. It has decreased from 9.22 (Mar 24) to 8.54, marking a decrease of 0.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.59. This value exceeds the healthy maximum of 50. It has increased from 57.49 (Mar 24) to 61.59, marking an increase of 4.10.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 58.61. This value exceeds the healthy maximum of 50. It has increased from 54.27 (Mar 24) to 58.61, marking an increase of 4.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 38.41. This value is below the healthy minimum of 40. It has decreased from 42.51 (Mar 24) to 38.41, marking a decrease of 4.10.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 41.39. This value is within the healthy range. It has decreased from 45.73 (Mar 24) to 41.39, marking a decrease of 4.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 172.37. This value is within the healthy range. It has increased from 136.66 (Mar 24) to 172.37, marking an increase of 35.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 124.75. This value is within the healthy range. It has increased from 97.48 (Mar 24) to 124.75, marking an increase of 27.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 63,674.71. It has increased from 55,125.76 (Mar 24) to 63,674.71, marking an increase of 8,548.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 9.42 (Mar 24) to 9.93, marking an increase of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.32. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 32.32, marking a decrease of 0.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 38.40. This value is within the healthy range. It has decreased from 42.50 (Mar 24) to 38.40, marking a decrease of 4.10.
- For Price / BV (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has decreased from 15.48 (Mar 24) to 15.43, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Abbott India Ltd:
- Net Profit Margin: 22.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 42.09% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 33.41% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 124.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 44.3 (Industry average Stock P/E: 50.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3, Corporate Park, Mumbai Maharashtra 400071 | investorrelations.india@abbott.com http://www.abbott.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Munir Shaikh | Chairman |
| Mr. Kartik Rajendran | Managing Director |
| Mr. Kaiyomarz Marfatia | Non Executive Director |
| Mr. Ambati Venu | Non Executive Director |
| Ms. Alison Davies | Non Executive Director |
| Ms. Anisha Motwani | Independent Director |
| Ms. Shalini Kamath | Independent Director |
| Mr. Sudarshan Jain | Independent Director |
FAQ
What is the intrinsic value of Abbott India Ltd?
Abbott India Ltd's intrinsic value (as of 24 October 2025) is 25598.63 which is 15.39% lower the current market price of 30,255.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 64,292 Cr. market cap, FY2025-2026 high/low of 37,000/25,260, reserves of ₹4,212 Cr, and liabilities of 5,917 Cr.
What is the Market Cap of Abbott India Ltd?
The Market Cap of Abbott India Ltd is 64,292 Cr..
What is the current Stock Price of Abbott India Ltd as on 24 October 2025?
The current stock price of Abbott India Ltd as on 24 October 2025 is 30,255.
What is the High / Low of Abbott India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Abbott India Ltd stocks is 37,000/25,260.
What is the Stock P/E of Abbott India Ltd?
The Stock P/E of Abbott India Ltd is 44.3.
What is the Book Value of Abbott India Ltd?
The Book Value of Abbott India Ltd is 1,992.
What is the Dividend Yield of Abbott India Ltd?
The Dividend Yield of Abbott India Ltd is 1.57 %.
What is the ROCE of Abbott India Ltd?
The ROCE of Abbott India Ltd is 46.2 %.
What is the ROE of Abbott India Ltd?
The ROE of Abbott India Ltd is 35.7 %.
What is the Face Value of Abbott India Ltd?
The Face Value of Abbott India Ltd is 10.0.